Chapter: 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models

Chapter: 2 EXECUTIVE SUMMARY

2.1. CXO PERSPECTIVE

Chapter: 3 MARKET OVERVIEW

3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS

3.2.1. Top investment pockets
3.2.2. Top winning strategies

3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS

3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities

Chapter: 4 GLOBAL FLOMOXEF SODIUM MARKET, BY PATEINT GROUP 

4.1. OVERVIEW

4.1.1. Key market trends
4.1.2. Key growth factors and opportunities
4.1.3. Market size and forecast

4.2. CHILDREN 

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ADULTS 

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

Chapter: 5 GLOBAL FLOMOXEF SODIUM MARKET, BY APPLICATION 

5.1. OVERVIEW

5.1.1. Key market trends
5.1.2. Key growth factors and opportunities
5.1.3. Market size and forecast

5.2. PNEUMONIA

5.2.1. Key market trends
5.2.2. Key growth factors and opportunities
5.2.3. Market size and forecast

5.3. PERITONITIS

5.3.1. Key market trends
5.3.2. Key growth factors and opportunities
5.3.3. Market size and forecast

5.4. THROAT DISORDERS

5.4.1. Key market trends
5.4.2. Key growth factors and opportunities
5.4.3. Market size and forecast

5.5. ASTHMA

5.5.1. Key market trends
5.5.2. Key growth factors and opportunities
5.5.3. Market size and forecast

5.6. OSTEOPOROSIS

5.6.1. Key market trends
5.6.2. Key growth factors and opportunities
5.6.3. Market size and forecast

5.7. OTHERS 

5.7.1. Key market trends
5.7.2. Key growth factors and opportunities
5.7.3. Market size and forecast

Chapter: 6 GLOBAL FLOMOXEF SODIUM MARKET, BY GEOGRAPHY

6.1. OVERVIEW
6.2. NORTH AMERICA

6.2.1. Key market trends
6.2.2. Key growth factors and opportunities
6.2.3. Market size and forecast

6.2.3.1. By Patient Group 
6.2.3.2. By Application 

6.2.4. U.S.

6.2.4.1. Market size and forecast, By Application 

6.2.5. Canada 

6.2.5.1. Market size and forecast, By Application 

6.2.6. Mexico

6.2.6.1. Market size and forecast, By Application 

6.3. EUROPE

6.3.1. Key market trends
6.3.2. Key growth factors and opportunities
6.3.3. Market size and forecast

6.3.3.1. By Patient Group 
6.3.3.2. By Application 

6.3.4. UK

6.3.4.1. Market size and forecast, By Application 

6.3.5. Germany 

6.3.5.1. Market size and forecast, By Application 

6.3.6. France 

6.3.6.1. Market size and forecast, By Application 

6.3.7. Spain 

6.3.7.1. Market size and forecast, By Application 

6.3.8. Italy

6.3.8.1. Market size and forecast, By Application 

6.3.9. Rest of Europe

6.3.9.1. Market size and forecast, By Application 

6.4. ASIA-PACIFIC

6.4.1. Key market trends
6.4.2. Key growth factors and opportunities
6.4.3. Market size and forecast

6.4.3.1. By Patient Group 
6.4.3.2. By Application 

6.4.4. China

6.4.4.1. Market size and forecast, By Application 

6.4.5. Japan

6.4.5.1. Market size and forecast, By Application 

6.4.6. India

6.4.6.1. Market size and forecast, By Application 

6.4.7. Australia

6.4.7.1. Market size and forecast, By Application 

6.4.8. South Korea

6.4.8.1. Market size and forecast, By Application 

6.4.9. Rest of Asia-Pacific

6.4.9.1. Market size and forecast, By Application 

6.5. LAMEA

6.5.1. Key market trends
6.5.2. Key growth factors and opportunities
6.5.3. Market size and forecast

6.5.3.1. By Patient Group 
6.5.3.2. By Application 

6.5.4. Brazil

6.5.4.1. Market size and forecast, By Application 

6.5.5. South Africa 

6.5.5.1. Market size and forecast, By Application 

6.5.6. Saudi Arabia 

6.5.6.1. Market size and forecast, By Application 

6.5.7. Rest of LAMEA

6.5.7.1. Market size and forecast, By Application 

Chapter: 7 COMPANY PROFILES

7.1. CHEMIELIVA PHARMACEUTICAL CO., LTD.

7.1.1. Operating business segments
7.1.2. Business performance
7.1.3. Key strategic moves and developments

7.2. CHEMOS GMBH & CO. KG

7.2.1. Operating business segments
7.2.2. Business performance
7.2.3. Key strategic moves and developments

7.3. CLEARSYNTH CANADA INC.

7.3.1. Operating business segments
7.3.2. Business performance
7.3.3. Key strategic moves and developments

7.4. FINIPHARMA LTD

7.4.1. Operating business segments
7.4.2. Business performance
7.4.3. Key strategic moves and developments

7.5. HANGZHOU J&H CHEMICAL CO., LTD.

7.5.1. Operating business segments
7.5.2. Business performance
7.5.3. Key strategic moves and developments

7.6. KINBESTER CO., LTD.

7.6.1. Operating business segments
7.6.2. Business performance
7.6.3. Key strategic moves and developments

7.7. LGM PHARMA

7.7.1. Operating business segments
7.7.2. Business performance
7.7.3. Key strategic moves and developments

7.8. NEBULA CHEMICALS CO, LTD.

7.8.1. Operating business segments
7.8.2. Business performance
7.8.3. Key strategic moves and developments

7.9. SHIONOGI & CO.

7.9.1. Operating business segments
7.9.2. Business performance
7.9.3. Key strategic moves and developments

7.10. YUNGJIN PHARM. CO.

7.10.1. Operating business segments
7.10.2. Business performance
7.10.3. Key strategic moves and developments